/Companies

Deciphera Pharmaceuticals

Waltham, US · Founded 2015 · Delaware LLC · 547 employees on LinkedIn · 4 known investors

Find your way into Deciphera Pharmaceuticals

Sign up to see every warm intro you have to Deciphera Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Deciphera Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Develops selective kinase inhibitors for cancer (QINLOCK); acquired by Ono Pharmaceuticals in 2024.

Founders & leadership

Deciphera Pharmaceuticals was founded in 2015 by Daniel F. Flynn, Ph.D..

DF
Daniel F. Flynn, Ph.D.Founder
OROliver Rosen, M.D.
Oliver Rosen, M.D.ExecutiveOliver Rosen is a physician-scientist with academic research focused on stem-cell transplantation and autoimmune disease treatment, who has served as an executive officer at Deciphera Pharmaceuticals and supported multiple capital rounds and public offerings totaling over $750 million.
TK
Thomas KellyExecutive
MTMichael Taylor
Michael TaylorExecutiveMichael Taylor is an executive and director at Deciphera Pharmaceuticals with a background in drug discovery and development, business development, and corporate management in the life sciences industry.

Board

MR
Michael RossBoard director
LR
Liam Ratcliffe, M.D., Ph.D.Board director
JM
John MartinBoard director
JA
James A. Bristol, Ph.D.Board director
DW
Dennis WalshBoard director

Investors · 4

Reported raises · per SEC filings

Form D private placements

$142.9M disclosed across 2 rounds · 2015–2017

▶$52.3MraisedJun 2017 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael RossDirector
  • Oliver Rosen, M.D.Executive Officer
  • Thomas KellyExecutive Officer
  • Patricia L. AllenDirector
  • John MartinDirector
  • Daniel L. Flynn, Ph.D.Executive Officer
  • Dennis WalshDirector
  • James A. Bristol, Ph.D.Director
  • Christopher MorlExecutive Officer
  • Michael D. Taylor, Ph.D.Executive Officer, Director
  • Liam Ratcliffe, M.D., Ph.D.Director
  • Edward J. Benz, Jr.Director
Offering amount
$52.3M
Amount sold
$52.3M
First sale
May 2017
Incorporated
Limited Liability Company, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$90.6MraisedJul 2016 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael RossDirector
  • Oliver Rosen, M.D.Executive Officer
  • Thomas KellyExecutive Officer
  • John MartinDirector
  • Daniel F. Flynn, Ph.D.Executive Officer
  • Liam Ratcliffe, M.D., Ph.D.Director
  • Michael TaylorExecutive Officer, Director
  • James A. Bristol, Ph.D.Director
  • Dennis WalshDirector
Offering amount
$90.6M
Amount sold
$90.6M
First sale
Sep 2015
Incorporated
Limited Liability Company, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Deciphera Pharmaceuticals do?
Develops selective kinase inhibitors for cancer (QINLOCK); acquired by Ono Pharmaceuticals in 2024.
Who founded Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals was founded by Daniel F. Flynn, Ph.D. in 2015.
Who are Deciphera Pharmaceuticals's investors?
Deciphera Pharmaceuticals's investors include Frazier Life Sciences, Viking Global, REDMILE, Viking Global Investors.
How much funding has Deciphera Pharmaceuticals raised?
Deciphera Pharmaceuticals has disclosed $142.9M raised across 2 rounds.
Where is Deciphera Pharmaceuticals headquartered?
Deciphera Pharmaceuticals is headquartered in Waltham, US.